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ABSTRACT
Background. Iron deficiency is a common complication in patients with polycythemia vera (PV). Unfortu-
nately, little is known about the pathomechanisms of iron deficiency in PV. There have been no studies in 
the last decade documenting iron disorders in PV, despite progress in understanding the iron metabolism 
and new laboratory techniques measuring iron parameters.
Objectives. The aim of this study was to assess the relationships between iron metabolism parameters, 
haematological and biochemical factors and clinical attributes in polycythemia vera patients with the use 
of cluster analysis (CA) and principal component analysis (PCA).
Patients and methods. The study was performed on 60 patients (F/M 26/34) aged 38–84 (66 ± 10) 
years. The following parameters were determined in blood samples: hepcidin, prohepcidin, iron, total 
iron binding capacity (TIBC), unsaturated iron binding capacity (UIBC), ferritin, soluble transferrin recep-
tor (sTfR), transferrin saturation (TfS), complete blood cell count, erythropoietin (Epo), uric acid, lactate 
dehydrogenase (LDH).
Results. The CA divided all the 17 parameters into three clusters and showed that hepcidin concentration 
is related to the duration of hydroxyurea therapy. PCA also revealed a positive correlation between hepcidin 
and therapy duration.
Conclusions. We demonstrated that CA and PCA are efficacious methods for assessing the relationship 
between iron metabolism parameters and clinical attributes in PV patients.
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Introduction
Polycythemia vera (PV) is currently classified as 
one of the myeloproliferative neoplasms (MPNs) and is 
characterised by marrow hyperplasia with an increased 
number of erythrocytes as well as leukocytes and plate-
lets in peripheral blood [1]. Several studies have shown 
that iron deficiency (ID) is a common disorder in poly-
cythemia vera patients, and can significantly influence 
their quality of life. Iron deficiency in polycythemia vera 
is usually a complication of expansive erythropoiesis in 
addition to phlebotomy and haemorrhage [2–5]. Unfor-
tunately, little is still known about the pathomechanisms 
of ID in polycythemia vera.
There have been no studies in the last decade doc-
umenting iron disorders in polycythemia vera, despite 
progress in understanding the iron metabolism and new 
laboratory techniques measuring iron parameters. That 
makes the studies on iron metabolism in polycythemia 
vera even more interesting.
The aim of this study was to assess the relationships 
between iron metabolism parameters, haematological 
and biochemical factors and clinical attributes in poly-
cythemia vera patients with the use of cluster analysis 
(CA) and principal component analysis (PCA).
Materials and methods
Patients
The study group comprised 60 patients with polycy-
themia vera (34 male, 26 female). The patients ranged 
in age from 38 to 84 years (66 ± 10). The diagnosis of 
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PV was based on the Polycythemia Vera Study Group 
Diagnostic Criteria for Polycythemia Vera and confirmed 
by trepanobiopsy. All the patients were followed in the 
haematology outpatient clinic. Physical and diagnostic 
examinations, consisting of complete blood cell count, 
uric acid concentration and lactate dehydrogenase 
concentration, were performed at regular intervals. The 
maximum patient follow-up period was 27 years, and the 
mean observation period was 7.4 years. Every patient 
from the study group was treated with hydroxyurea 
(HU) alone or HU with supplemental phlebotomy. The 
biochemical analyses were performed with blood serum 
samples. All procedures in the study were approved by 
the local ethics committee. Informed written consent 
was obtained after the purpose, nature, and potential 
risks had been explained to the subjects.
Analytical methods
The biochemical analyses were performed on blood 
samples. Blood samples were drawn from an antecubi-
tal vein between 8 a.m. and 10 a.m. with minimal venous 
stasis and then centrifuged. Serum was stored at –80°C 
until the analysis.
Serum hepcidin concentrations were quantified 
using ELISA kit (Hepcidin ELISA, EIA-4705, DRG Instru-
ments GmbH, Germany). Levels of prohepcidin were 
determined by a stable ELISA (Hepcidin Prohormone 
ELISA, DRG Instruments GmbH, Germany).
Serum iron concentrations, values of unsaturated 
iron capacity (UIBC), total iron capacity (TIBC), transfer-
rin saturation (TfS), uric acid and lactate dehydrogenase 
(LDH) were measured on the Architect c8000 System 
(Abbott Laboratories, USA). 
Serum ferritin was quantified using the DRG Ferritin 
kit (EIA-1872, DRG International, Inc., USA). Serum 
soluble transferrin receptor (sTfR) concentrations 
were examined by an enzyme-linked immunosorbent 
assay (the Human sTfR ELISA, BioVendor Laboratory 
Medicine Inc., Czech Republic). Erythropoietin (EPO) 
concentrations were quantified using ELISA kit (EPO 
ELISA, Roche Diagnostics GmbH, Germany).
Complete blood cell count was measured on whole 
blood samples using ADVIA 120 (Bayer Diagnostics, USA).
Statistical analysis
All statistical analyses were performed using the 
software Statistica 10.0 (Stat–Soft, Krakow, Poland). 
Results are presented as mean ± SD when the data 
demonstrated a normal distribution, or as medians 
(Q1–lower quartile/Q3–upper quartile) due to their being 
abnormally skew of the data. All of the iron metabolism 
parameters, haematological and biochemical factors 
and clinical attributes were used in multivariate data 
analysis. Ward’s minimum-variance CA and PCA were 
used for appraisal of dependence between laboratory 
and clinical parameters.
Results
Table 1 shows the values of all laboratory and clinical 
parameters in patients with polycythemia vera.
CA divided all the laboratory and clinical parameters 
into three clusters (Fig. 1):
 — Cluster 1 — age, duration of therapy, hepcidin, uric 
acid, LDH;
 — Cluster 2 — sTfR, TIBC, UIBC, RBC, HGB, HCT;
 — Cluster 3 — prohepcidin, EPO, ferritin, iron, TfS, 
MCV.
The result of the PCA is a 2D scatter plot of the 
cases in the space formed by the first two principal 
components (PC1 and PC2), which are orthogonal 
and uncorrelated (Fig. 2). The first two PCs explain 
49.46% of the variation. PV patients form a relatively 
homogeneous group.
The other result of the PCA analysis (correlation 
circle, Fig. 3) was interpreted as follows [6]:
 — when two variables are close to each other — they 
are strongly positively correlated;
 — when two variables are on opposite sides — they 
are strongly negatively correlated;
 — when two variables are orthogonal to each other 
– they are not correlated.
Discussion
Multivariate analysis captures dependencies be-
tween parameters which are often invisible in a classic 
two-parametric analysis. CA combines the most similar 
factors into clusters. In our study, the separation of clus-
ters provides a lack of homogeneity of the examined iron 
parameters, other laboratory parameters and clinical 
features that characterise patients with polycythemia 
vera. CA divided all of the 17 parameters into three clus-
ters (Fig. 1). In polycythemia vera patients, laboratory 
parameters assessing their iron metabolism have been 
classified into all three clusters. The concentration of 
hepcidin was included in one set with concentration of 
uric acid, concentration of LDH, and with such clinical 
parameters as age and therapy duration. The concen-
tration of soluble transferrin receptor and values of TIBC 
and UIBC formed a cluster with RBC, HGB and HCT. 
The third cluster contained prohepcidin, ferritin, iron, 
transferrin saturation as well as erythropoietin concen-
tration and values of MCV.
The interpretation of the results will be limited 
mainly to the parameters contained in the first cluster 
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Figure 1. Clustering dendrogram obtained with Ward’s method considering all laboratory and clinical attributes
Figure 2. Scores of the first two principal components for laboratory and clinical data (the numbers are those of the 
PV patients included in the study)
(hepcidin, uric acid, LDH, age, duration of therapy). The 
main reason for such a restriction is the essential role 
of hepcidin in iron metabolism regulation. Hepcidin is 
an antimicrobial peptide hormone mainly synthesised 
in the liver as an 84-amino acid prepropeptide, which 
is subsequently processed into a 60- to 64-residue 
prohepcidin peptide and then finally cleaved into 
25-amino acid hepcidin [7, 8]. Hepcidin is known as the 
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main regulator of serum iron concentrations. Generally, 
hepcidin causes a decrease in serum iron. The mech-
anism of hepcidin activity depends on its interactions 
with its receptor ferroportin. Ferroportin is an iron ex-
porter expressed on the surface of reticulo endothelial 
macrophages, hepatocytes, duodenal enterocytes and 
placenta cells. Hepcidin regulates post-translationally 
ferroportin expression. After binding to ferroportin, hep-
cidin is internalised and degraded in endolysosomes 
together with ferroportin, which in turn blocks the iron 
efflux from cells into plasma [9–11]. 
Unfortunately, a lot remains to be discovered re-
garding the biology and function of hepcidin. Further 
studies are needed to define precisely hepcidin’s role 
in iron metabolism, not only in physiological but also in 
pathological conditions. To the best of our knowledge, 
we are the first to evaluate hepcidin concentration in the 
serum of polycythemia vera patients.
CA showed a relationship between the concentration 
of hepcidin and duration of therapy (cluster 1, Fig. 1). 
PCA also revealed a positive correlation between the 
mentioned parameters (Fig. 3). All the PV patients in 
the study were on maintenance therapy with hydroxy-
urea (from 1–27 years), and some of them had been 
previously treated by phlebotomy. Therefore, we can 
exclude phlebotomy as the factor influencing iron status 
in this particular group of PV patients. 
The results of our study suggest that long-term HU 
treatment may disturb iron metabolism homeostasis 
through the constant stimulation of hepcidin activity. HU 
is a cytotoxic and antimitotic drug, which inhibits DNA 
synthesis by blocking ribonucleotide reductase [12]. 
Data dedicated to the impact of HU on iron status is lim-
ited. Clinical observations show that HU may decrease 
iron absorption from food. It has been confirmed that 
HU has side effects on the digestive system such as 
nausea, vomiting, diarrhoea, stomatitis, loss of appetite, 
flatulence and constipation [13]. Moreover, the hyd-
roxamic functional group of hydroxyurea (-CO-NHOH) 
has the ability of strong chelation of divalent iron. After 
stimulation from HU, large amounts of nitric oxide are 
formed [14]. Nitric oxide stimulates the binding of IRP 
to IRE which limits ferritin mRNA translation and at the 
same time protects transferrin receptor mRNA from 
degradation [15, 16]. 
These findings may lead to the conclusion that HU 
may be treated as a potential factor involved in iron 
deficiency formation in polycythemia vera patients. In 
addition, the results of the present study confirm that 
many patients with PV suffer from iron deficiency. Ana-
lysis of the results showed the broad ranges of ferritin 
concentration values in patients with polycythemia vera 
— 0.48 — 188.11 ng/mL (Tab. 1). We can speculate that 
HU is one of the factors responsible for such a condi-
tion. Unfortunately, a comparison of those results with 
other papers is impossible because there have been 
no studies on the impact of HU on iron metabolism in 
PV patients.
The projection of the laboratory and clinical variables 
in the first two PCs space (Fig. 3) shows no correlation 
between hepcidin and its prohormone. Prohepcidin is 
a hepcidin precursor and undergoes a post-translational 
modification by furin to biologically active 25-amino 
acid hepcidin [17]. A high linkage distance between 
clusters 1 and 3 in CA also indicates that hepcidin is 
not dependent on prohepcidin located in the 3rd cluster 
(Fig. 1). Our results agree with other multicentre stud-
ies. No correlation between hepcidin and prohepcidin 
levels has been established so far [18, 19]. It should be 
stressed that prohepcidin concentration did not reflect 
the level of the active form — 25 amino acid hepcidin 
accurately. This may suggest the involvement of other 
factors responsible for the biochemical conversion of 
prohepcidin into hepcidin.
Regulatory mechanisms of iron status in polycythemia 
vera patients are unusual. Some of the findings have con-
firmed that the JAK2 mutation may be involved in the regu-
lation of iron status in myeloproliferative disorders [20, 21]. 
The relationship between the JAK2 mutation and the 
regulatory axis hepcidin-ferroportin and IRP proteins 
remains unexplored in polycythemia vera. In physio-
logical conditions, kinase JAK2 is involved in erythro-
poietin receptor signalling. It is also associated with the 
regulation of iron metabolism, because it phosphory-
lates ferroportin in response to hepcidin [22–25]. We 
can assume that the constitutive activation of kinase 
JAK2 as a result of mutations JAK2V617F can lead to 
Figure 3. Projection of the laboratory and clinical 
variables in the two first principal components space (the 
interpretation was described in the ‘Results’ chapter)
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Table 1. Laboratory and clinical characteristics of polycythemia vera patients
Parameter N
X ± SD
Me (Q1/Q3) Min – Max
Iron status parameters
Hepcidin (ng/mL) 57 103.68 (84.37/118.28) 38.46–192.36
Prohepcidin (ng/mL) 58 93.62 (80.64/105.67) 33.13–447.87
Serum iron (μg/dL) 59 82.00 (36.00/115.00) 9.00–210.00
TIBC (μg/dL) 59 330.00 (279.00/414.00) 184.00–498.00
UIBC (μg/dL) 60 233.50 (172.50/352.00) 29.00–473.00
Ferritin (ng/mL) 56 27.99 (5.81/64.62) 0.48–188.11
sTfR (μg/mL) 59 2.27 (1.48/4.66) 0.11–10.21
TfS (%) 59 26.25 (8.27/41.09) 2.04–87.87
Haematological parameters
RBC (× 106/μL) 60 5.36 (4.67/6.22) 3.39–8.55
HGB (g/dL) 60 17.50 ± 2.24 12.10–22.10
HCT (%) 60 55.00 (48.10/58.75) 36.10–70.30
MCV (fL) 60 99.17 ± 12.28 69.10–125.90
Biochemical parameters
EPO (mIU/mL) 57 12.97 (10.37/19.13) 1.99–45.23
Uric acid (mg/dL) 60 5.49 (4.53/6.96) 3.39–10.29
LDH (U/L) 60 296 (235.5/359) 149–912
Clinical parameters
Age (years) 60 65.95 ± 10.28 38–84
Duration of therapy (years) 60 7.38 ± 6.06 1–27
uncontrolled phosphorylation of ferroportin which, in 
turn, disturbs the mechanisms responsible for iron 
efflux from cells. This process may be a signal to an 
enhanced prohepcidin conversion to hepcidin, resulting 
in increased hepcidin expression.
CA also showed relations between concentrations 
of uric acid, LDH and therapy duration (Fig. 1). Such 
results are not surprising, since elevated concentrations 
of uric acid and LDH are typical laboratory changes for 
PV patients treated with HU. Uric acid is a product of 
purine metabolism generated during the breakdown of 
nucleid acids (DNA and RNA) and ATP. In polycythemia 
vera, chemotherapeutic treatments, for example HU, 
cause a marked increase in the excretion of uric acid 
resulting from the nucleic acid metabolism [26, 27]. 
Another consequence of HU treatment is an increase 
in values of LDH concentration, which reflects intravas-
cular haemolysis and tissue breakdown [27]. 
Conclusions
CA and PCA proved to be very useful methods in the 
interpretation of large amounts of laboratory and clinical 
data on associations of iron metabolism parameters 
with other biochemical and haematological factors and 
clinical attributes in polycythemia vera patients.
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